These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28405611)

  • 1. Long-term follow-up of a randomized AAV2-
    Niethammer M; Tang CC; LeWitt PA; Rezai AR; Leehey MA; Ojemann SG; Flaherty AW; Eskandar EN; Kostyk SK; Sarkar A; Siddiqui MS; Tatter SB; Schwalb JM; Poston KL; Henderson JM; Kurlan RM; Richard IH; Sapan CV; Eidelberg D; During MJ; Kaplitt MG; Feigin A
    JCI Insight; 2017 Apr; 2(7):e90133. PubMed ID: 28405611
    [No Abstract]   [Full Text] [Related]  

  • 2. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.
    LeWitt PA; Rezai AR; Leehey MA; Ojemann SG; Flaherty AW; Eskandar EN; Kostyk SK; Thomas K; Sarkar A; Siddiqui MS; Tatter SB; Schwalb JM; Poston KL; Henderson JM; Kurlan RM; Richard IH; Van Meter L; Sapan CV; During MJ; Kaplitt MG; Feigin A
    Lancet Neurol; 2011 Apr; 10(4):309-19. PubMed ID: 21419704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
    Kaplitt MG; Feigin A; Tang C; Fitzsimons HL; Mattis P; Lawlor PA; Bland RJ; Young D; Strybing K; Eidelberg D; During MJ
    Lancet; 2007 Jun; 369(9579):2097-105. PubMed ID: 17586305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
    Marks WJ; Bartus RT; Siffert J; Davis CS; Lozano A; Boulis N; Vitek J; Stacy M; Turner D; Verhagen L; Bakay R; Watts R; Guthrie B; Jankovic J; Simpson R; Tagliati M; Alterman R; Stern M; Baltuch G; Starr PA; Larson PS; Ostrem JL; Nutt J; Kieburtz K; Kordower JH; Olanow CW
    Lancet Neurol; 2010 Dec; 9(12):1164-1172. PubMed ID: 20970382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease.
    Diaz-Nido J
    Curr Opin Investig Drugs; 2010 Jul; 11(7):813-22. PubMed ID: 20571977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism.
    Emborg ME; Carbon M; Holden JE; During MJ; Ma Y; Tang C; Moirano J; Fitzsimons H; Roitberg BZ; Tuccar E; Roberts A; Kaplitt MG; Eidelberg D
    J Cereb Blood Flow Metab; 2007 Mar; 27(3):501-9. PubMed ID: 16835631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain networks underlying the clinical effects of long-term subthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT.
    Sestini S; Ramat S; Formiconi AR; Ammannati F; Sorbi S; Pupi A
    J Nucl Med; 2005 Sep; 46(9):1444-54. PubMed ID: 16157526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.
    Warren Olanow C; Bartus RT; Baumann TL; Factor S; Boulis N; Stacy M; Turner DA; Marks W; Larson P; Starr PA; Jankovic J; Simpson R; Watts R; Guthrie B; Poston K; Henderson JM; Stern M; Baltuch G; Goetz CG; Herzog C; Kordower JH; Alterman R; Lozano AM; Lang AE
    Ann Neurol; 2015 Aug; 78(2):248-57. PubMed ID: 26061140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Dafsari HS; Silverdale M; Strack M; Rizos A; Ashkan K; Mahlstedt P; Sachse L; Steffen J; Dembek TA; Visser-Vandewalle V; Evans J; Antonini A; Martinez-Martin P; Ray-Chaudhuri K; Timmermann L;
    Mov Disord; 2018 Mar; 33(3):421-430. PubMed ID: 29465787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease.
    Kleiner-Fisman G; Fisman DN; Sime E; Saint-Cyr JA; Lozano AM; Lang AE
    J Neurosurg; 2003 Sep; 99(3):489-95. PubMed ID: 12959435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of bilateral subthalamic nucleus stimulation in Chinese Parkinson's disease patients.
    Li J; Zhang Y; Li Y
    Br J Neurosurg; 2015 Jun; 29(3):329-33. PubMed ID: 25812021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson's disease: one year follow-up of a randomised observer-blind multi centre trial.
    Esselink RA; de Bie RM; de Haan RJ; Steur EN; Beute GN; Portman AT; Schuurman PR; Bosch DA; Speelman JD
    Acta Neurochir (Wien); 2006 Dec; 148(12):1247-55; discussion 1255. PubMed ID: 17072792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.
    Rodriguez-Oroz MC; Zamarbide I; Guridi J; Palmero MR; Obeso JA
    J Neurol Neurosurg Psychiatry; 2004 Oct; 75(10):1382-5. PubMed ID: 15377681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.
    Feigin A; Kaplitt MG; Tang C; Lin T; Mattis P; Dhawan V; During MJ; Eidelberg D
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19559-64. PubMed ID: 18042721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
    Moro E; Esselink RJ; Benabid AL; Pollak P
    Brain; 2002 Nov; 125(Pt 11):2408-17. PubMed ID: 12390968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease.
    Moro E; Lozano AM; Pollak P; Agid Y; Rehncrona S; Volkmann J; Kulisevsky J; Obeso JA; Albanese A; Hariz MI; Quinn NP; Speelman JD; Benabid AL; Fraix V; Mendes A; Welter ML; Houeto JL; Cornu P; Dormont D; Tornqvist AL; Ekberg R; Schnitzler A; Timmermann L; Wojtecki L; Gironell A; Rodriguez-Oroz MC; Guridi J; Bentivoglio AR; Contarino MF; Romito L; Scerrati M; Janssens M; Lang AE
    Mov Disord; 2010 Apr; 25(5):578-86. PubMed ID: 20213817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontal FDG-PET activity correlates with cognitive outcome after STN-DBS in Parkinson disease.
    Kalbe E; Voges J; Weber T; Haarer M; Baudrexel S; Klein JC; Kessler J; Sturm V; Heiss WD; Hilker R
    Neurology; 2009 Jan; 72(1):42-9. PubMed ID: 19122029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
    Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
    J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.